This is consistent with the Ki-67 staining results in a large CGGA cohort of clinical samples [27, 51], whereas Ki-67 staining was not detected in 48.4% of the PM gliomas (N = 126), 31% of the EM gliomas (N = 83) showed a high extent of Ki-67 staining (Fig. 5B and Additional file 1: Fig. S14), potentially accounting for the differential aggressiveness between the EM and PM gliomas [17, 18]. Here, MKI67 is linked to central nervous system cancer.